Product: CD8 Antibody
Catalog: AF5126
Description: Rabbit polyclonal antibody to CD8
Application: WB IHC
Cited expt.: WB, IHC
Reactivity: Human, Mouse, Rat
Mol.Wt.: 25 kDa; 26kD(Calculated).
Uniprot: P01732
RRID: AB_2837612

View similar products>>

   Size Price Inventory
 100ul $280 In stock
 200ul $350 In stock

Lead Time: Same day delivery

For pricing and ordering contact:
Local distributors

Product Info

Source:
Rabbit
Application:
WB 1:500-1:2000, IHC 1:50-1:200
*The optimal dilutions should be determined by the end user.
*Tips:

WB: For western blot detection of denatured protein samples. IHC: For immunohistochemical detection of paraffin sections (IHC-p) or frozen sections (IHC-f) of tissue samples. IF/ICC: For immunofluorescence detection of cell samples. ELISA(peptide): For ELISA detection of antigenic peptide.

Reactivity:
Human,Mouse,Rat
Clonality:
Polyclonal
Specificity:
CD8 Antibody detects endogenous levels of total CD8.
RRID:
AB_2837612
Cite Format: Affinity Biosciences Cat# AF5126, RRID:AB_2837612.
Conjugate:
Unconjugated.
Purification:
The antiserum was purified by peptide affinity chromatography using SulfoLink™ Coupling Resin (Thermo Fisher Scientific).
Storage:
Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.
Alias:

Fold/Unfold

alpha polypeptide (p32); CD8; CD8 antigen alpha polypeptide; CD8 antigen alpha polypeptide (p32); CD8a; CD8A antigen; CD8A molecule; CD8A_HUMAN; Leu2; Leu2 T lymphocyte antigen; Ly3; LYT3; MAL; OKT8 T cell antigen; OTTHUMP00000160760; OTTHUMP00000160764; OTTHUMP00000203528; OTTHUMP00000203721; p32; T cell antigen Leu2; T cell co receptor; T-cell surface glycoprotein CD8 alpha chain; T-lymphocyte differentiation antigen T8/Leu-2; T8 T cell antigen; T8/Leu-2 T-lymphocyte differentiation antigen;

Immunogens

Immunogen:

A synthesized peptide derived from human CD8, corresponding to a region within the internal amino acids.

Uniprot:
Gene(ID):
Expression:
P01732 CD8A_HUMAN:

CD8 on thymus-derived T-cells usually consists of a disulfide-linked alpha/CD8A and a beta/CD8B chain. Less frequently, CD8 can be expressed as a CD8A homodimer. A subset of natural killer cells, memory T-cells, intraepithelial lymphocytes, monocytes and dendritic cells expresses CD8A homodimers. Expressed at the cell surface of plasmacytoid dendritic cells upon herpes simplex virus-1 stimulation.

Description:
Identifies cytotoxic/suppressor T-cells that interact with MHC class I bearing targets. CD8 is thought to play a role in the process of T-cell mediated killing. CD8 alpha chains binds to class I MHC molecules alpha-3 domains.
Sequence:
MALPVTALLLPLALLLHAARPSQFRVSPLDRTWNLGETVELKCQVLLSNPTSGCSWLFQPRGAAASPTFLLYLSQNKPKAAEGLDTQRFSGKRLGDTFVLTLSDFRRENEGYYFCSALSNSIMYFSHFVPVFLPAKPTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCNHRNRRRVCKCPRPVVKSGDKPSLSARYV

Research Backgrounds

Function:

Integral membrane glycoprotein that plays an essential role in the immune response and serves multiple functions in responses against both external and internal offenses. In T-cells, functions primarily as a coreceptor for MHC class I molecule:peptide complex. The antigens presented by class I peptides are derived from cytosolic proteins while class II derived from extracellular proteins. Interacts simultaneously with the T-cell receptor (TCR) and the MHC class I proteins presented by antigen presenting cells (APCs). In turn, recruits the Src kinase LCK to the vicinity of the TCR-CD3 complex. LCK then initiates different intracellular signaling pathways by phosphorylating various substrates ultimately leading to lymphokine production, motility, adhesion and activation of cytotoxic T-lymphocytes (CTLs). This mechanism enables CTLs to recognize and eliminate infected cells and tumor cells. In NK-cells, the presence of CD8A homodimers at the cell surface provides a survival mechanism allowing conjugation and lysis of multiple target cells. CD8A homodimer molecules also promote the survival and differentiation of activated lymphocytes into memory CD8 T-cells.

PTMs:

Palmitoylated, but association with CD8B seems to be more important for the enrichment of CD8A in lipid rafts.

O-glycosylated.

Phosphorylated in cytotoxic T-lymphocytes (CTLs) following activation.

Subcellular Location:

Cell membrane>Single-pass type I membrane protein.
Note: CD8A localizes to lipid rafts only when associated with its partner CD8B.

Secreted.

Extracellular region or secreted Cytosol Plasma membrane Cytoskeleton Lysosome Endosome Peroxisome ER Golgi apparatus Nucleus Mitochondrion Manual annotation Automatic computational assertionSubcellular location
Tissue Specificity:

CD8 on thymus-derived T-cells usually consists of a disulfide-linked alpha/CD8A and a beta/CD8B chain. Less frequently, CD8 can be expressed as a CD8A homodimer. A subset of natural killer cells, memory T-cells, intraepithelial lymphocytes, monocytes and dendritic cells expresses CD8A homodimers. Expressed at the cell surface of plasmacytoid dendritic cells upon herpes simplex virus-1 stimulation.

Research Fields

· Environmental Information Processing > Signaling molecules and interaction > Cell adhesion molecules (CAMs).   (View pathway)

· Human Diseases > Immune diseases > Primary immunodeficiency.

· Organismal Systems > Immune system > Antigen processing and presentation.   (View pathway)

· Organismal Systems > Immune system > Hematopoietic cell lineage.   (View pathway)

· Organismal Systems > Immune system > T cell receptor signaling pathway.   (View pathway)

References

1). Tumor cells impair immunological synapse formation via central nervous system-enriched metabolite. Cancer cell, 2024 (PubMed: 38821061) [IF=48.8]

2). Multifunctional 3D-printed scaffolds eradiate orthotopic osteosarcoma and promote osteogenesis via microwave thermo-chemotherapy combined with immunotherapy. Biomaterials, 2023 (PubMed: 37506512) [IF=12.8]

3). Dietary palmitoleic acid reprograms gut microbiota and improves biological therapy against colitis. Gut microbes, 2023 (PubMed: 37203220) [IF=12.2]

4). Alantolactone-loaded chitosan/hyaluronic acid nanoparticles suppress psoriasis by deactivating STAT3 pathway and restricting immune cell recruitment. Asian Journal of Pharmaceutical Sciences, 2022 (PubMed: 35582636) [IF=10.7]

Application: IF/ICC    Species: mouse    Sample: skin

Fig. 8| CHALT attenuates splenomegaly and immune cell recruitment in IMQ-induced skin. On Day 7, (A) the spleens were collected and photographed, and (B) the weight ratio of spleen/body was calculated. Immunfluorescence staining of (C) CD 4 and (E) CD 8 in the skin, and the relative amount of (D) CD 4 and (F) CD 8 was quantified (the normal group as the control).

5). Harnessing the power of traceable system C-GAP: homologous-targeting to fire up T-cell immune responses with low-dose irradiation. Journal of nanobiotechnology, 2025 (PubMed: 40075499) [IF=10.6]

6). Harnessing the power of traceable system C-GAP: homologous-targeting to fire up T-cell immune responses with low-dose irradiation. Journal of nanobiotechnology, 2025 (PubMed: 40075499) [IF=10.2]

Application: IF/ICC    Species: Mouse    Sample:

Fig. 7 In Vivo Experiments on C-GAP-Induced ICD in OSCC of C3H Mice. A Representative Images of Immunohistochemical Staining for γ-H2AX in Tumor Tissue from C3H Mice in Different Groups (n = 4). B Representative Images of Immunohistochemical Staining for HMGB1 in Tumor Tissue from C3H Mice in Different Groups (n = 4). C Representative Images of Immunofluorescence Staining for CD3e and CD8 in Tumor Tissue from C3H Mice in Different Groups (n = 4)

7). Enhancing immunotherapy efficacy in colorectal cancer: targeting the FGR-AKT-SP1-DKK1 axis with DCC-2036 (Rebastinib). Cell death & disease, 2025 (PubMed: 39788945) [IF=8.1]

8). SIRPα antibody combined with oncolytic virus OH2 protects against tumours by activating innate immunity and reprogramming the tumour immune microenvironment. BMC Medicine, 2022 (PubMed: 36310169) [IF=7.0]

Application: IHC    Species: Mouse    Sample:

Fig. 5M-IHC and IHC staining of the anti-SIRPα antibody treatment model. A Representative M-IHC results of the OH2 combined anti-SIRPα antibody group, OH2 combined isotype, OH2 group, and control group with larger tumour volume sat the initial treatment. CD8, green, CD16, sky blue, F4/80, purple, CD86, orange, and CD206, red. Scale bar, 100μm. B Quantitative results of NK cell (CD16) staining in the OH2 combined anti-SIRPα antibody group, OH2 combined isotype, OH2 group, and control group. n=3 samples/group. C Quantitative result of M2 macrophage (F4/80+CD206+) staining in the OH2 combined anti-SIRPα antibody group, OH2 combined isotype, OH2 group, and control group. n=3 samples/group. D Quantitative results of M1 macrophage (F4/80+CD86+) staining in the OH2 combined anti-SIRPα antibody group, OH2 combined isotype, OH2 group, and control group. n=3 samples/group. E Quantitative results of CD8 T cell staining in the OH2 combined anti-SIRPα antibody group, OH2 combined Isotype, OH2 group, and control group. n=3 samples/group. F Representative IHC staining for CD8, CD16, F4/80, CD86, and CD206 of the OH2 combined anti-SIRPα antibody group, OH2 combined isotype group, OH2 group, and control group with larger tumour volumes at the initial treatment. Original magnification, ×200. n=5 samples/group. G Quantitative results of CD8, CD16, F4/80, CD86 and CD206 staining in the OH2 combined anti-SIRPα antibody group, OH2 combined isotype, OH2 group and control group. n=5 samples/group. Statistical analysis was performed using ANOVA with multiple comparisons. ns, no significant differences, *, p<0.05, **, p<0.01, ***, p<0.001, ****, p<0.0001 (proportion represented the percentage of the cell to the total number of cells)

9). Icariside II attenuates cerebral ischemia/reperfusion-induced blood–brain barrier dysfunction in rats via regulating the balance of MMP9/TIMP1. Acta Pharmacologica Sinica, 2020 (PubMed: 32488170) [IF=6.9]

10). Hepatitis B virus-mediated sodium influx contributes to hepatic inflammation via synergism with intrahepatic danger signals. iScience, 2023 (PubMed: 38283328) [IF=5.8]

Application: IF/ICC    Species: Mouse    Sample:

Figure 6 NLRP3 inflammasome-mediated effector cytokines contributed to liver injury and hepatic inflammation in patients with severe hepatitis B (A and B) Correlation between IL-18 level and ALT (A) or M30 (B) levels was analyzed in the plasma of inpatients with active severe hepatitis B. (C–F, H, and I) Liver tissue slides derived from HC and patients with minimal and severe hepatitis B were assayed using TSA-amplified multiplexed immunofluorescence staining. On the same slide, CD68 (red), CD8 (green), cleaved IL-1β (pink), IL-18 (brown), and DAPI (blue) were stained (D) and counted using ImageJ software in random 10 (resolution: 20-micron) visual fields per each patient. The number of CD68+ particles (E) and CD8+ particles (F) derived from each representative patient with different extents of hepatic inflammation were compared. Then, the data derived from 3 patients with severe hepatitis B was pooled to analyze the correlation between CD68+ cells and effector cytokines (IL-1β+ particles and IL-18+ particles) (C), the correlation between CD8+ particles and CD68+ particles (H) and IL-1β+ particles (I) with GraphPad Prism 8.0. (G) Heatmap of Xcell-analyzing data shows intrahepatic immune cell infiltration in patients with different extents of hepatic inflammation as shown in Table 4. Each panel indicates an individual with/without HBV infection. HC, healthy control. ∗p < 0.05 and ∗∗p < 0.01.

Load more

Restrictive clause

 

Affinity Biosciences tests all products strictly. Citations are provided as a resource for additional applications that have not been validated by Affinity Biosciences. Please choose the appropriate format for each application and consult Materials and Methods sections for additional details about the use of any product in these publications.

For Research Use Only.
Not for use in diagnostic or therapeutic procedures. Not for resale. Not for distribution without written consent. Affinity Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Affinity Biosciences, Affinity Biosciences Logo and all other trademarks are the property of Affinity Biosciences LTD.